Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK7 inhibitors as anticancer drugs

8 May 2020

Abstract excerpt

Cyclin-dependent kinase 7 (CDK7), along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs progression through the cell cycle via T-loop phosphorylation of cell cycle CDKs. CAK is also a component of the general transcription factor, TFIIH. CDK7-mediated phosphorylation of RNA polymerase II (Pol II) at active gene promoters permits transcription. Cell cycle dysregulation is an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32385714
DOI: 10.1007/s10555-020-09885-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK7 inhibitors as anticancer drugsPMID 32385714Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

CDK7 in breast cancer: mechanisms of action and therapeutic potentialSemantic proximity Read ↗

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Semantic proximity Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7Semantic proximity Read ↗

Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer TherapeuticsSemantic proximity Read ↗

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapySemantic proximity Read ↗

Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer TherapySemantic proximity Read ↗

Cell cycle regulation and anticancer drug discoverySemantic proximity Read ↗

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An UpdateSemantic proximity Read ↗

CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic PredictivitySemantic proximity Read ↗

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.